RecruitingPhase 2

Study of Dextromethorphan in OCD and Related Disorders

United States60 participantsStarted 2022-01-20

Plain-language summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD) * Living within California * Capacity to provide informed consent Exclusion Criteria: * Current bipolar disorder or psychotic disorder * Active moderate or severe substance use disorder, lifetime severe substance use disorder * Pregnant or nursing women * Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start * Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

What they're measuring

Improvement in OCD or related disorder symptoms as measured by the Y-BOCS

Timeframe: Change from baseline will be assessed at 4 weeks and at 8 weeks.

Trial details

NCT IDNCT04899687

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-01

Contact for this trial

Pavithra Mukunda, MS

650 497 2578 ocdresearch@stanford.edu

View on ClinicalTrials.gov More Obsessive-Compulsive Disorder trials